A hypercoagulable state associated with coronavirus disease 2019 (COVID-19) has been
well documented and is believed to be strongly supported by a proinflammatory state. The …

Shortly after the emergence of coronavirus disease 2019 (COVID-19) in late 2019, clinicians
rapidly recognized an apparent association between the disease and both arterial and …

The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in significant morbidity
and mortality worldwide. Although initial reports concentrated on severe respiratory illness …

Coronavirus disease 2019 (COVID-19) is a systemic disease that can be life-threatening
involving immune and inflammatory responses, and that can result in potentially lethal …

At this time last year, it was farfetched if not impossible to think of the immense changes and
challenges to people and the society in 2020. Social distancing has become the norm in …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Background Previous studies demonstrate a reduced risk of thrombosis and mortality with
anticoagulant treatment in patients with COVID-19 than in those without anticoagulation …

Abstract Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including …

Severe acute respiratory syndrome coronavirus 2 infections are associated with greater risk
of both arterial and venous thromboembolic events. Pathophysiology and Clinical …

Background Hospitalized patients with COVID‐19 suffered initially from high rates of venous
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …